Chrysalis DNX Transgenics Science

DNX and its subsidiaries, DNX Transgenic Sciences and Pharmakon Research International, have established credibility as global providers of preclinical drug development services, a precursor to human clinical trials. The company’s services encompass a wide range of capabilities including toxicology, pharmacology, pharmacokinetics, continuous infusion management technology, the use of genetically engineered rodent models for evaluating new drugs and therapies, immunotoxicology, and specialized pharmacological analyses. Through preclinical laboratories located in Lyon, France; Scranton, Pennsylvania; and Princeton, New Jersey, DNX provides preclinical services to over 250 pharmaceutical and biotechnology companies across 16 countries.